[go: up one dir, main page]

RU2001107149A - TAUROLIDINE AND / OR TAURULTS AGAINST INFECTIOUS ULCER DISEASE OR INFECTIOUS GASTRITIS - Google Patents

TAUROLIDINE AND / OR TAURULTS AGAINST INFECTIOUS ULCER DISEASE OR INFECTIOUS GASTRITIS

Info

Publication number
RU2001107149A
RU2001107149A RU2001107149/14A RU2001107149A RU2001107149A RU 2001107149 A RU2001107149 A RU 2001107149A RU 2001107149/14 A RU2001107149/14 A RU 2001107149/14A RU 2001107149 A RU2001107149 A RU 2001107149A RU 2001107149 A RU2001107149 A RU 2001107149A
Authority
RU
Russia
Prior art keywords
antimicrobial drug
administered
use according
taurolidine
proton pump
Prior art date
Application number
RU2001107149/14A
Other languages
Russian (ru)
Other versions
RU2227033C2 (en
Inventor
Рольф ПФИРРМАНН
Original Assignee
Эд Гейштлих Зёне Аг Фюр Хемише Индустрие
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,115 external-priority patent/US6117868A/en
Application filed by Эд Гейштлих Зёне Аг Фюр Хемише Индустрие filed Critical Эд Гейштлих Зёне Аг Фюр Хемише Индустрие
Publication of RU2001107149A publication Critical patent/RU2001107149A/en
Application granted granted Critical
Publication of RU2227033C2 publication Critical patent/RU2227033C2/en

Links

Claims (12)

1. Применение антимикробного лекарственного препарата, выбранного из группы, состоящей из тауролидина, таурултама или их комбинаций, при производстве терапевтического средства для использования при лечении инфекционного желудочно-кишечного заболевания инфицированной микробами ткани желудочно-кишечного тракта у млекопитающих, вызываемого микроорганизмами, выбранными из Helicobacter pylori, Helicobacter heilmanni или их комбинации.1. The use of an antimicrobial drug selected from the group consisting of taurolidine, taurultam, or combinations thereof, in the manufacture of a therapeutic agent for use in the treatment of an infectious gastrointestinal disease of microbial-infected gastrointestinal tissue in mammals caused by microorganisms selected from Helicobacter pylori , Helicobacter heilmanni or combinations thereof. 2. Применение по п. 1, отличающееся тем, что вышеуказанный антимикробный лекарственный препарат вводят в форме таблеток, капсул, жидкости, суспензии или сиропа. 2. The use according to claim 1, characterized in that the above antimicrobial drug is administered in the form of tablets, capsules, liquid, suspension or syrup. 3. Применение по п. 1 или 2, отличающееся тем, что вышеуказанный антимикробный лекарственный препарат вводится в дозе, эквивалентной примерно 200-1000 мг тауролидина. 3. The use according to claim 1 or 2, characterized in that the above antimicrobial drug is administered in a dose equivalent to about 200-1000 mg of taurolidine. 4. Применение по п. 3, отличающееся тем, что вышеуказанное антимикробное соединение вводится в дозе, эквивалентной примерно 300-500 мг тауролидина. 4. The use according to claim 3, characterized in that the above antimicrobial compound is administered in a dose equivalent to about 300-500 mg of taurolidine. 5. Применение по любому из предшествующих пунктов, отличающееся тем, что вышеуказанный антимикробный лекарственный препарат вводят в комбинации с фармацевтически приемлемым лекарственным препаратом, покрывающим поверхность желудка, который образует защитное покрытие на слизистой желудка пациента для предотвращения раздражения желудка вышеуказанным антимикробным лекарственным препаратом. 5. The use according to any one of the preceding paragraphs, characterized in that the above antimicrobial drug is administered in combination with a pharmaceutically acceptable drug covering the surface of the stomach, which forms a protective coating on the gastric mucosa of the patient to prevent irritation of the stomach with the above antimicrobial drug. 6. Применение по любому из предшествующих пунктов, отличающееся тем, что вышеуказанный антимикробный лекарственный препарат вводят в комбинации с фармацевтически приемлемым желудочным антацидным средством, нейтрализующим кислоту в желудочном соке. 6. The use according to any one of the preceding paragraphs, characterized in that the above antimicrobial drug is administered in combination with a pharmaceutically acceptable gastric antacid that neutralizes the acid in the gastric juice. 7. Применение по любому из предшествующих пунктов, отличающееся тем, что вышеуказанный антимикробный лекарственный препарат вводят в комбинации с ингибитором протонной помпы. 7. The use according to any one of the preceding paragraphs, characterized in that the above antimicrobial drug is administered in combination with a proton pump inhibitor. 8. Применение по п. 7, отличающееся тем, что вышеуказанный ингибитор протонной помпы является Омепразолом или Рабепразолом. 8. The use according to claim 7, characterized in that the above proton pump inhibitor is Omeprazole or Rabeprazole. 9. Применение по п. 8, отличающееся тем, что вышеуказанный ингибитор протонной помпы является Рабепразолом. 9. The use of claim 8, wherein said proton pump inhibitor is Rabeprazole. 10. Фармацевтическая композиция, включающая антимикробный лекарственный препарат, выбранный из тауролидина, таурултама или их комбинаций, и фармацевтически приемлемый ингибитор протонной помпы, по выбору в сочетании с одним или несколькими фармацевтически приемлемыми соединениями, выбранными из группы, состоящей из: а) лекарственного препарата, покрывающего поверхность желудка, который образует защитное покрытие на слизистой желудка пациента для предотвращения раздражения желудка указанным антимикробным лекарственным препаратом; и б) желудочного антацидного средства, нейтрализующего кислоту желудочного сока. 10. A pharmaceutical composition comprising an antimicrobial drug selected from taurolidine, taurultam, or combinations thereof, and a pharmaceutically acceptable proton pump inhibitor, optionally in combination with one or more pharmaceutically acceptable compounds selected from the group consisting of: a) a drug, covering the surface of the stomach, which forms a protective coating on the mucous membrane of the patient’s stomach to prevent irritation of the stomach with the specified antimicrobial drug; and b) a gastric antacid that neutralizes the acid of the gastric juice. 11. Фармацевтическая композиция по п. 10, отличающаяся тем, что вышеуказанный ингибитор протонной помпы является Омепразолом или Рабепразолом. 11. The pharmaceutical composition according to p. 10, characterized in that the above proton pump inhibitor is Omeprazole or Rabeprazole. 12. Фармацевтическая композиция по п. 11, отличающаяся тем, что вышеуказанный ингибитор протонной помпы является Рабепразолом. 12. The pharmaceutical composition according to p. 11, characterized in that the above proton pump inhibitor is Rabeprazole.
RU2001107149/15A 1998-09-16 1999-09-13 Taurolidine and/or taurultam in treatment of infectious ulcer disease of infectious gastritis RU2227033C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15445198A 1998-09-16 1998-09-16
US09/154,451 1998-09-16
US09/316,115 US6117868A (en) 1998-09-16 1999-05-20 Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US09/316,115 1999-05-20

Publications (2)

Publication Number Publication Date
RU2001107149A true RU2001107149A (en) 2003-04-20
RU2227033C2 RU2227033C2 (en) 2004-04-20

Family

ID=26851461

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001107149/15A RU2227033C2 (en) 1998-09-16 1999-09-13 Taurolidine and/or taurultam in treatment of infectious ulcer disease of infectious gastritis

Country Status (8)

Country Link
US (1) US6117868A (en)
EP (1) EP1112074B1 (en)
JP (1) JP4981208B2 (en)
CA (1) CA2344308C (en)
DE (1) DE69916629T2 (en)
ES (1) ES2219061T3 (en)
RU (1) RU2227033C2 (en)
WO (1) WO2000015232A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2265437C2 (en) * 2003-07-02 2005-12-10 Суханов Александр Владимирович Method for treating gastric and duodenal diseases caused by helicobacter pylori

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
JP2001122777A (en) * 1999-10-27 2001-05-08 Nagase & Co Ltd Antiulcer agent
CN100519525C (en) * 1999-12-06 2009-07-29 葛兰素集团有限公司 Aromatic sulfones and their medical use
DE60030770T2 (en) * 1999-12-06 2007-09-06 Rhode Island Hospital USE OF TAUROLIDINE OR TAURULTAM FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OVARIAN CARCINOMES
FR2803206A1 (en) * 1999-12-30 2001-07-06 Aventis Pharma Sa New composition, used in in vitro or ex vivo cellular transfection, comprises a nucleic acid and a mineral particle with an exchangeable layer structure
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
EP1450814B1 (en) 2001-10-01 2016-11-30 Geistlich Pharma AG Methods of inhibiting metastases
FI20021819A0 (en) * 2002-10-14 2002-10-14 Pekka Untamo Heino Preparation to enhance alcohol metabolism
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
JPWO2008075621A1 (en) * 2006-12-20 2010-04-08 協和化学工業株式会社 Antacid
RU2410100C2 (en) 2009-03-30 2011-01-27 Александр Владимирович Диковский Pharmaceutical composition of proton pump inhibitor and prebiotic for treating gastric and duodenal ulcers
TWI590829B (en) * 2010-02-24 2017-07-11 艾米斯菲爾科技股份有限公司 Oral b12 therapy
EP2601947A1 (en) * 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
DK2861573T3 (en) * 2012-06-18 2017-11-13 Geistlich Pharma Ag OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCES
EP3377067A4 (en) * 2015-10-07 2019-07-31 Cormedix Inc. SKIN PENETRATION FORMULATION BASED ON TAUROLIDINE
CN117159461A (en) * 2023-07-26 2023-12-05 合肥远志医药科技开发有限公司 Aluminum magnesium carbonate suspension and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124285A (en) * 1964-10-06 1968-08-21 Geistlich Soehne Ag Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
DE3533612A1 (en) * 1985-09-20 1987-04-02 Johannes Reinmueller INNOVATIVE USE OF TAUROLIN
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) * 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
KR910700059A (en) * 1989-01-19 1991-03-13 조브스트 크라우스코프 Use of dimethylpolysiloxane for the treatment of disorders of the gastrointestinal tract
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
TW276996B (en) * 1992-04-24 1996-06-01 Astra Ab
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
JPH09121890A (en) * 1995-10-30 1997-05-13 Mitsubishi Kagaku B C L:Kk Method for detecting Helicobacter bacteria
SE507682C2 (en) * 1996-03-29 1998-07-06 Marcin Krotkiewski Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and peptic ulcer disease containing a mixture of ammonium bismuth citrate and an alginate
JPH1017471A (en) * 1996-07-04 1998-01-20 Yoshitomi Pharmaceut Ind Ltd Pyridine compound combination drug
JP3677376B2 (en) * 1996-08-13 2005-07-27 武田薬品工業株式会社 Medicine
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2265437C2 (en) * 2003-07-02 2005-12-10 Суханов Александр Владимирович Method for treating gastric and duodenal diseases caused by helicobacter pylori

Similar Documents

Publication Publication Date Title
RU2001107149A (en) TAUROLIDINE AND / OR TAURULTS AGAINST INFECTIOUS ULCER DISEASE OR INFECTIOUS GASTRITIS
RU2227033C2 (en) Taurolidine and/or taurultam in treatment of infectious ulcer disease of infectious gastritis
CA2506930C (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
WO2002098352A3 (en) PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
JP2002525266A5 (en)
TW359614B (en) Composition containing benzimidazole compounds for rectal administration
US20040131676A1 (en) Dosage forms containing a PPI, NSAID, and buffer
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
PL173485B1 (en) Pharmaceutic agent for treating gastritis and peptic ulcers
US20090075950A1 (en) Dosage Forms Containing A PPI, NSAID And A Buffer
JPH04230330A (en) Combination drug and method for relieving gastroenteric symptom arising from nonsteroidal anti inflammatory drug
JP3018160B2 (en) Drug for reducing dysmenorrhea and / or premenstrual syndrome
RU99100397A (en) NEW CONNECTIONS
JP2004534050A (en) Methods for preventing and treating diseases and conditions associated with cellular stress
KR19990023021A (en) New medicinal uses
JPH04230329A (en) Drug combinations and methods for alleviating gastrointestinal pain symptoms caused by non-steroidal anti-inflammatory drugs
RU2005122465A (en) (-) - TENATOPRAZOL ENANTIOMER AND ITS APPLICATION IN THERAPY
US5834004A (en) Enteral composition comprising dimethicone and a photosensitizer and a method of delivery
US20060141027A1 (en) Sublingual administration of non-steroidal anti-inflammatory pharmacological substances
JP2003517434A5 (en)
ES2306905T3 (en) USE OF TENATOPRAZOL FOR THE TREATMENT OF GASTROESOFAGIC REFLUX.
RU2004121780A (en) METHOD OF TREATMENT
KR20050098831A (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
RU2238742C2 (en) Method for treating and preventing relapses of uncomplicated forms of gastric and duodenal ulcerous disease
RU2002121267A (en) METHOD FOR PREVENTION AND TREATMENT OF GASTRIC ULCERS IN ANIMALS